Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab

(2018) Manali Mukherjee et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Associations between blood eosinophils and decline in lung function among adults with and without asthma

(2018) Robert J. Hancox et al.   EUROPEAN RESPIRATORY JOURNAL

The construction and validation of the Severe Asthma Questionnaire

(2018) Michael E. Hyland et al.   EUROPEAN RESPIRATORY JOURNAL

Oral corticosteroid exposure and adverse effects in asthmatic patients

(2018) Patrick W. Sullivan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

(2018) J Mark FitzGerald et al.   Lancet Respiratory Medicine

Biomarkers for severe eosinophilic asthma

(2017) Steven W. Yancey et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Seasonal and geographic variations in the incidence of asthma exacerbations in the United States

(2017) M. Gerhardsson de Verdier et al.   JOURNAL OF ASTHMA

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe and Difficult-to-Treat Asthma in Adults

(2017) Elliot Israel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of New Therapies for Severe Asthma

(2017) Merritt L. Fajt et al.   Allergy Asthma & Immunology Research

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

(2017) Anirban Basu et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

(2016) Hector G Ortega et al.   Lancet Respiratory Medicine

The prevalence of severe refractory asthma

(2015) Pieter-Paul W. Hekking et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

(2015) David B Price et al.   Lancet Respiratory Medicine

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis

(2014) Pranabashis Haldar et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales

(2014) Michael E. Hyland et al.   QUALITY OF LIFE RESEARCH

Impact of Asthma Exacerbations and Asthma Triggers on Asthma-related Quality of Life in Patients with Severe or Difficult-to-Treat Asthma

(2014) Allan T. Luskin et al.   Journal of Allergy and Clinical Immunology-In Practice

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Global asthma prevalence in adults: findings from the cross-sectional world health survey

(2012) Teresa To et al.   BMC PUBLIC HEALTH

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

(2012) Philip H. Quanjer et al.   EUROPEAN RESPIRATORY JOURNAL

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria

(2011) Stephanie Korn et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma

(2009) Prescott G. Woodruff et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

(2008) Miguel L. Stein et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Use of a preference-based measure of health (EQ-5D) in COPD and asthma

(2008) A. Simon Pickard et al.   RESPIRATORY MEDICINE